Navigation Links
Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
Date:11/12/2009

SAN DIEGO, Nov. 12 /PRNewswire-FirstCall/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH), will present results of its ongoing human clinical Phase I/II open-label dose-ranging trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC) on November 16 at the American Association for Cancer Research - Molecular Targets and Cancer Therapeutics Conference in Boston. Apoptone, a novel steroid that is an analog of part of the dihydrotestosterone metabolic pathway, stimulates ERK1 signal transduction that counter-regulates PI3K, and thereby initiating tumor cell apoptosis. Apoptone has demonstrated activity in animal models of CRPC, the results of which were recently published in the British Journal of Cancer and the journal Neoplasia.

Concurrently with its lead program Apoptone, Hollis-Eden Pharmaceuticals is pursuing clinical development of a second oral small-molecule candidate, Triolex®, from its synthetic steroid library. Triolex decreases macrophage infiltration into fatty tissues and pro-inflammatory processes. The lead indication for Triolex is Type 2 diabetes. A Phase II trial (HE3286-0401) in obese, insulin-resistant diabetic patients is fully enrolled and should be completed in the first quarter of 2010. A Phase I trial (HE3286-0102) to assess safety and early activity in obese insulin-resistant, pre-diabetic subjects is complete, with final analysis in progress. Additional trials were initiated during 2008 in rheumatoid arthritis (RA) and ulcerative colitis (UC).

James Frincke, Ph.D., Chief Executive Officer of Hollis-Eden Pharmaceuticals commented: "We have reduced our burn rate to enable operations focused on our lead programs to continue into the latter half of 2010. We intend to use data from our ongoing trials to eng
'/>"/>

SOURCE Hollis-Eden Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price
2. Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO
3. Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
4. NeoGenomics To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 18, 2009
5. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
6. Viron to Present Data from Phase II Trial at American Heart Association Conference
7. Curemark Presents at Springboard Enterprises Life Sciences Forum
8. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 16, 2009
9. NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009
10. CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response
11. Helix BioPharma to Present at Merriman Curhan Fords Investor Summit 2009 on November 10th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... (PRWEB) July 13, 2014 2014 Deep ... is a professional and in-depth study on the current ... China. , The report provides a basic overview of ... Global market analysis and Chinese domestic market analysis are ... competitive landscape of the market. A comparison between the ...
(Date:7/12/2014)... 2014 This report covers ... in the life science industry. Continuous innovation ... reagents market towards remarkable growth. The stakeholders ... of life science reagents. , Brows full ... . , The global life science reagents ...
(Date:7/11/2014)... BEACH, Fla. , July 11, 2014 /PRNewswire-iReach/ -- ... of high-quality peptides that are used solely in scientific ... honor two successful years in business, Maxim Peptide, which ... has just launched a new and updated website that ... research blog section has been updated with fascinating articles ...
(Date:7/11/2014)... , July 11, 2014 , Not ... in, into or from any jurisdiction where to do so ... jurisdiction.  Shire plc ("Shire" or the "Company") (LSE: ... this afternoon.  Shire confirms it has held a meeting with ... by Shire without the prior agreement or approval of AbbVie. ...
Breaking Biology Technology:2014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 22014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 3Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Shire plc - Statement re: Media Speculation 2
... ... ... ... , ...
... ... for different body types and shampoo bottles shaped to closely match the size of ... to redesign armor for troops in Afghanistan. , ... Madison, NJ, USA (PRWEB) February 24, 2010 -- Interactive exhibits make learning ...
... ... ... , ... , , , , ...
Cached Biology Technology:Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 2Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 3Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 4Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 5Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 6Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 7Science by the Seat of Their Pants - Museum Goers, Industry and the Military Take Pressure Off with Body Mapping 2Science by the Seat of Their Pants - Museum Goers, Industry and the Military Take Pressure Off with Body Mapping 3Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 2Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 3Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 4Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 5
(Date:7/13/2014)... more effective treatments for cachexia, a profound wasting of ... cancer patients, raising their risk of death, according to ... been tried to reverse the condition, which may cause ... but none have had great success. , Scientists reporting ... Nature , led by Bruce Spiegelman, PhD, demonstrated that ...
(Date:7/11/2014)... new report from the Wildlife Conservation Society shows ... help economically valuable species such as lobster, conch, ... help re-colonize nearby reef areas. , The reporttitled ... systematic review of research literature from no-take areas ... Dr. Craig Dahlgren, a recognized expert in marine ...
(Date:7/11/2014)... OAK RIDGE, Tenn., July 11, 2014--Researchers at the ... received eight R&D 100 awards, presented by R&D ... innovations. , "These awards recognize the tremendous ... Energy Ernest Moniz. "Research and development at the ... its energy challenges and pursue the scientific and ...
Breaking Biology News(10 mins):Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... A new neuroimaging study conducted by researchers from the ... de Montral at the International laboratory for Brain Music ... amusic individuals have more grey matter in specific regions ... the right interior frontal gyrus and the right auditory ...
... Approximately one in every 500 to 650 baby boys is ... genetic code that until a few years ago was thought ... no longer the case. A recent conference hosted by NewYork-Presbyterian ... raising awareness of the condition and the recent availability of ...
... chew up rattlesnake skin and smear it on their ... a new study by researchers at UC Davis. ... UC Davis, observed ground squirrels (Spermophilus beecheyi) and rock ... picking up pieces of shed snakeskin, chewing it and ...
Cached Biology News:Jingle bells not merry for tone-deaf individuals 2Jingle bells not merry for tone-deaf individuals 3Physician-scientists seek solutions to reproductive problems related to chromosomal variations 2Physician-scientists seek solutions to reproductive problems related to chromosomal variations 3
...
...
...
... Streptavidin Sepharose High Performance, 5 ... media used in HiTrap Streptavidin columns ... compounds.Ideal for packing into Tricorn 5/50 ... when larger scale purifications are required.Extremely ...
Biology Products: